DP023 | LUSPATERCEPT FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS WITH DEL5Q, REFRACTORY/RESISTANT/INTOLERANT TO PRIOR TREATMENTS (QOL-ONE PHOENIX)

Background: Myelodysplastic neoplasms (MDS) with deletion 5q (del5q) are characterized by red blood cell transfusion dependence (RBC-TD and about one third of patients are refractory/resistant/ineligible to lenalidomide. Luspatercept is approved for lower risk MDS requiring transfusions. We present...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	E.N. Oliva, M. Riva, C. Frairia, E. Crisà, A. Poloni, C. Alati, I. Capodanno, F. Pane, A. Castelli, C. Gurnari, M.T. Voso, G. Zini, M.G. D’errigo, C. Mammì, G. Iannì, D. Griguolo, M. Marchetti, S. Barillà, I. E. Bova, M.C. Cannatà, L. Rizzo, I.M. Delfino, B. Fattizzo
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Ferrata Storti Foundation 2025-09-01
Rangatū:	Haematologica
Urunga tuihono:	https://haematologica.org/article/view/12787
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!